In last trading session, Aldeyra Therapeutics Inc (NASDAQ:ALDX) saw 0.58 million shares changing hands with its beta currently measuring 0.78. Company’s recent per share price level of $6.91 trading at $0.1 or 1.47% at ring of the bell on the day assigns it a market valuation of $412.59M. That closing price of ALDX’s stock is at a discount of -4.2% from its 52-week high price of $7.20 and is indicating a premium of 60.78% from its 52-week low price of $2.71. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.72 million shares which gives us an average trading volume of 463.78K if we extend that period to 3-months.
For Aldeyra Therapeutics Inc (ALDX), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 2 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 2 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.24 in the current quarter.
Aldeyra Therapeutics Inc (NASDAQ:ALDX) trade information
Upright in the green during last session for gaining 1.47%, in the last five days ALDX remained trading in the green while hitting it’s week-highest on Wednesday, 03/12/25 when the stock touched $6.91 price level, adding 4.03% to its value on the day. Aldeyra Therapeutics Inc’s shares saw a change of 38.48% in year-to-date performance and have moved 8.82% in past 5-day. Aldeyra Therapeutics Inc (NASDAQ:ALDX) showed a performance of 14.69% in past 30-days. Number of shares sold short was 3.61 million shares which calculate 8.42 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 12 to the stock, which implies a rise of 42.42% to its current value. Analysts have been projecting 12 as a low price target for the stock while placing it at a high target of 12. It follows that stock’s current price would drop -73.66% in reaching the projected high whereas dropping to the targeted low would mean a loss of -73.66% for stock’s current value.
5 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of -800k for the same. And 5 analysts are in estimates of company making revenue of 54.8M in the next quarter.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 15.99% during past 5 years.
Aldeyra Therapeutics Inc (NASDAQ:ALDX)’s Major holders
Insiders are in possession of 2.43% of company’s total shares while institution are holding 63.08 percent of that, with stock having share float percentage of 64.65%. Investors also watch the number of corporate investors in a company very closely, which is 63.08% institutions for Aldeyra Therapeutics Inc that are currently holding shares of the company. PERCEPTIVE ADVISORS LLC is the top institutional holder at ALDX for having 9.28 million shares of worth $30.7 million. And as of 2024-06-30, it was holding 15.6121 of the company’s outstanding shares.
The second largest institutional holder is KNOLL CAPITAL MANAGEMENT, LLC, which was holding about 5.48 million shares on 2024-06-30. The number of shares represents firm’s hold over 9.2158 of outstanding shares, having a total worth of $18.12 million.
On the other hand, Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 1.76 shares of worth $12.15 million or 2.95% of the total outstanding shares. The later fund manager was in possession of 1.36 shares on Dec 31, 2024 , making its stake of worth around $9.4 million in the company or a holder of 2.28% of company’s stock.
